Skip to main content

Advertisement

SpringerLink
Log in

Rab14 is overexpressed in ovarian cancers and promotes ovarian cancer proliferation through Wnt pathway

  • Original Article
  • Published:
Tumor Biology

Abstract

The Rab GTPase family protein Rab14 has been implicated in cancer development. However, its clinical significance in ovarian cancers and its biological effects have not been examined. The present study aims to examine the clinical significance, biological roles, and molecular mechanism of Rab14 in ovarian cancer progression. We examined expression pattern of Rab14 in 122 cases of ovarian cancer specimens using immunohistochemistry and found Rab14 overexpression correlated with FIGO stage (p = 0.0041). We depleted Rab14 in SKOV3 cells using siRNA and overexpressed Rab14 in SW626 cells. Knockdown of Rab14 inhibited cell growth and invasion while its overexpression facilitated cell growth and invasion. In addition, Rab14 overexpression increased paclitaxel resistance in SW626 cells while its depletion reduced drug resistance. Then, we investigated the role of Rab14 in the regulation of WNT/β-catenin signaling, demonstrating Rab14 overexpression regulated GSK3β phosphorylation and nuclear β-catenin accumulation. Rab14 depletion inhibited while its overexpression enhanced TCF transcriptional activity with corresponding change of Wnt target genes including MMP7 and c-myc. Wnt inhibitor abolished the effect of Rab14 on cell proliferation and Wnt target genes. In conclusion, the present study demonstrated that Rab14 promotes aggressiveness of ovarian cancer cell through, at least partly, Wnt signaling pathway.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.

    Article  PubMed  Google Scholar 

  2. Permuth-Wey J, Sellers TA. Epidemiology of ovarian cancer. Methods Mol Biol. 2009;472:413–37.

    Article  PubMed  Google Scholar 

  3. Wang YF, Lang HY, Yuan J, et al. Overexpression of keratin 17 is associated with poor prognosis in epithelial ovarian cancer. Tumour Biol. 2013;34(3):1685–9.

    Article  CAS  PubMed  Google Scholar 

  4. Darcy KM, Birrer MJ. Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies. Gynecol Oncol. 2010;117(3):429–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Despierre E, Lambrechts D, Neven P, et al. The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment. Gynecol Oncol. 2010;117(2):358–65.

    Article  CAS  PubMed  Google Scholar 

  6. Fang Y, Li Z, Wang X, et al. CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis. Tumour Biol. 2012;33(6):2299–306.

    Article  CAS  PubMed  Google Scholar 

  7. Zhao Y, Chen S, Gou WF, et al. Aberrant Beclin 1 expression is closely linked to carcinogenesis, differentiation, progression, and prognosis of ovarian epithelial carcinoma. Tumour Biol. 2014;35(3):1955–64.

    Article  CAS  PubMed  Google Scholar 

  8. Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiol Rev. 2001;81(1):153–208.

    CAS  PubMed  Google Scholar 

  9. Ming Z, Guo C, Jiang M, et al. Bioinformatics analysis of Rab GDP dissociation inhibitor beta and its expression in non-small cell lung cancer. Diagn Pathol. 2014;9:201.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Jin L, Huo Y, Zheng Z, et al. Down-regulation of Ras-related protein Rab 5C-dependent endocytosis and glycolysis in cisplatin-resistant ovarian cancer cell lines. Mol Cell Proteomics. 2014;13(11):3138–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Ye F, Tang H, Liu Q, et al. miR-200b as a prognostic factor in breast cancer targets multiple members of RAB family. J Transl Med. 2014;12:17.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Ho JR, Chapeaublanc E, Kirkwood L, et al. Deregulation of Rab and Rab effector genes in bladder cancer. PLoS One. 2012;7(6):e39469.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Subramani D, Alahari SK. Integrin-mediated function of Rab GTPases in cancer progression. Mol Cancer. 2010;9:312.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Chia WJ, Tang BL. Emerging roles for Rab family GTPases in human cancer. Biochim Biophys Acta. 2009;1795(2):110–6.

    CAS  PubMed  Google Scholar 

  15. Cheng KW, Lahad JP, Gray JW, et al. Emerging role of RAB GTPases in cancer and human disease. Cancer Res. 2005;65(7):2516–9.

    Article  CAS  PubMed  Google Scholar 

  16. Zhao Z, Liu XF, Wu HC, et al. Rab5a overexpression promoting ovarian cancer cell proliferation may be associated with APPL1-related epidermal growth factor signaling pathway. Cancer Sci. 2010;101(6):1454–62.

    Article  CAS  PubMed  Google Scholar 

  17. Fan Y, Wang L, Han X, et al. Rab25 is responsible for phosphoinositide 3-kinase/AKTmediated cisplatin resistance in human epithelial ovarian cancer cells. Mol Med Rep. 2015;11(3):2173–8.

    CAS  PubMed  Google Scholar 

  18. Liu Y, Tao X, Jia L, et al. Knockdown of RAB25 promotes autophagy and inhibits cell growth in ovarian cancer cells. Mol Med Rep. 2012;6(5):1006–12.

    CAS  PubMed  Google Scholar 

  19. Fan Y, Xin XY, Chen BL, et al. Knockdown of RAB25 expression by RNAi inhibits growth of human epithelial ovarian cancer cells in vitro and in vivo. Pathology. 2006;38(6):561–7.

    Article  PubMed  Google Scholar 

  20. Wang R, Wang ZX, Yang JS, et al. MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14. Oncogene. 2011;30(23):2644–58.

    Article  CAS  PubMed  Google Scholar 

  21. Psyrri A, Bamias A, Yu Z, et al. Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer. Clin Cancer Res. 2005;11(23):8384–90.

    Article  CAS  PubMed  Google Scholar 

  22. Bedrosian I, Lu KH, Verschraegen C, et al. Cyclin E deregulation alters the biologic properties of ovarian cancer cells. Oncogene. 2004;23(15):2648–57.

    Article  CAS  PubMed  Google Scholar 

  23. Dhar KK, Branigan K, Howells RE, et al. Prognostic significance of cyclin D1 gene (CCND1) polymorphism in epithelial ovarian cancer. Int J Gynecol Cancer. 1999;9(4):342–7.

    Article  PubMed  Google Scholar 

  24. Marone M, Scambia G, Giannitelli C, et al. Analysis of cyclin E and CDK2 in ovarian cancer: gene amplification and RNA overexpression. Int J Cancer. 1998;75(1):34–9.

    Article  CAS  PubMed  Google Scholar 

  25. Baekelandt M, Holm R, Trope CG, et al. Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: an immunohistochemical study. Clin Cancer Res. 1999;5(10):2848–53.

    CAS  PubMed  Google Scholar 

  26. Anttila MA, Kosma VM, Hongxiu J, et al. p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer. Br J Cancer. 1999;79(11–12):1870–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Al-Alem LF, McCord LA, Southard RC, et al. Activation of the PKC pathway stimulates ovarian cancer cell proliferation, migration, and expression of MMP7 and MMP10. Biol Reprod. 2013;89(3):73.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Schummer M, Drescher C, Forrest R, et al. Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125. Gynecol Oncol. 2012;125(1):65–9.

    Article  CAS  PubMed  Google Scholar 

  29. Bodnar L, Stanczak A, Cierniak S, et al. Wnt/beta-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer. J Ovarian Res. 2014;7:16.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Yoshioka S, King ML, Ran S, et al. WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/beta-catenin pathway. Mol Cancer Res. 2012;10(3):469–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Badiglian Filho L, Oshima CT, De Oliveira Lima F, et al. Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer. Oncol Rep. 2009;21(2):313–20.

    PubMed  Google Scholar 

  32. Nagaraj AB, Joseph P, Kovalenko O, et al. Critical role of Wnt/beta-catenin signaling in driving epithelial ovarian cancer platinum resistance. Oncotarget. 2015;6(27):23720–34.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Benelli R, Monteghirfo S, Vene R, et al. The chemopreventive retinoid 4HPR impairs prostate cancer cell migration and invasion by interfering with FAK/AKT/GSK3beta pathway and beta-catenin stability. Mol Cancer. 2010;9:142.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Luo J. Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. Cancer Lett. 2009;273(2):194–200.

    Article  CAS  PubMed  Google Scholar 

  35. Yook JI, Li XY, Ota I, et al. A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells. Nat Cell Biol. 2006;8(12):1398–406.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

This study was supported by the China NSFC project (No.81302272). We thank Dr. Y Wang and Dr. Y Liu for technical assistance of results evaluation

Author information

Authors and Affiliations

  1. Department of Gynaecology and Obstetrics, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China

    Rui Hou, Zhuo Yang, Shizhuo Wang & Qifang Liu

  2. Department of Ultrasonography, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China

    Luo Jiang

Authors
  1. Rui Hou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luo Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhuo Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shizhuo Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Qifang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rui Hou.

Ethics declarations

Conflict of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hou, R., Jiang, L., Yang, Z. et al. Rab14 is overexpressed in ovarian cancers and promotes ovarian cancer proliferation through Wnt pathway. Tumor Biol. 37, 16005–16013 (2016). https://doi.org/10.1007/s13277-016-5420-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-016-5420-4

Keywords

Search

Navigation